Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chi

Showing results (241-250 of 410) with videos related to

Pageof 41
Sort By:
European Urology|January 30, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 TrialJohann S de Bono, Meng He, Zhen Shi, et al.
Oncotarget|February 13, 2014
Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancerFrancesco Crea, Akira Watahiki, Luca Quagliata, et al.
Genome Biology|January 28, 2016
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patientsNada Lallous, Stanislav V Volik, Shannon Awrey, et al.
Pediatric Blood & Cancer|February 10, 2021
Outcomes after first relapse of childhood intracranial ependymomaJessica W Tsai, Neevika Manoharan, Sanda Alexandrescu, et al.
Prostate Cancer and Prostatic Diseases|November 21, 2019
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancerWilliam S Chen, Eric L Feng, Rahul Aggarwal, et al.
Diabetes & Metabolism|November 27, 2010
Increased serum retinol-binding protein-4 levels in pregnant women with and without gestational diabetes mellitusY-X Su, J Hong, Q Yan, et al.
Investigational New Drugs|May 19, 2015
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195B J Eigl, S North, E Winquist, et al.
The Lancet. Oncology|May 29, 2025
Health-related quality of life, pain, and symptomatic skeletal events with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trialKarim Fizazi, Michael J Morris, Neal D Shore, et al.
European Urology|March 6, 2017
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate CancerMatti Annala, Werner J Struss, Evan W Warner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
<i>BRCA2</i>, <i>ATM</i>, and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical AggressionEvan Warner, Cameron Herberts, Simon Fu, et al.
Pageof 41

Showing results (241-250 of 410) with videos related to

Sort By:
Pageof 41
European Urology|January 30, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 TrialJohann S de Bono, Meng He, Zhen Shi, et al.
Oncotarget|February 13, 2014
Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancerFrancesco Crea, Akira Watahiki, Luca Quagliata, et al.
Genome Biology|January 28, 2016
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patientsNada Lallous, Stanislav V Volik, Shannon Awrey, et al.
Pediatric Blood & Cancer|February 10, 2021
Outcomes after first relapse of childhood intracranial ependymomaJessica W Tsai, Neevika Manoharan, Sanda Alexandrescu, et al.
Prostate Cancer and Prostatic Diseases|November 21, 2019
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancerWilliam S Chen, Eric L Feng, Rahul Aggarwal, et al.
Diabetes & Metabolism|November 27, 2010
Increased serum retinol-binding protein-4 levels in pregnant women with and without gestational diabetes mellitusY-X Su, J Hong, Q Yan, et al.
Investigational New Drugs|May 19, 2015
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195B J Eigl, S North, E Winquist, et al.
The Lancet. Oncology|May 29, 2025
Health-related quality of life, pain, and symptomatic skeletal events with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trialKarim Fizazi, Michael J Morris, Neal D Shore, et al.
European Urology|March 6, 2017
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate CancerMatti Annala, Werner J Struss, Evan W Warner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
<i>BRCA2</i>, <i>ATM</i>, and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical AggressionEvan Warner, Cameron Herberts, Simon Fu, et al.
Pageof 41